Publications by authors named "Bijou Fontanet"

Claim this Profile
S
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.
Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Hervé Ghesquières, Frédéric Peyrade, Fontanet Bijou

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA.
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, Fontanet Bijou, Cédric Rossi

Cancer Epidemiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Fontanet Bijou

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort.
Christelle Cantrelle, Aurélien Belot, Alain Monnereau, Fontanet Bijou, Cédric Rossi

Cancer Epidemiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.
Pablo Mozas, Romain Ould Ammar, Loïc Chartier, Loretta Nastoupil, Emmanuel Bachy, Fontanet Bijou

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma).
Katell Le Dû, Adrien Chauchet, Sophie Sadot-Lebouvier, Olivier Fitoussi, Bijou Fontanet

JMIR Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Fontanet Bijou

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.
Amélie Anota, Mathurine Basset, Emilie Charton, Côme Bommier, Fabio Efficace, Fontanet Bijou

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study.
David Morland, Lukshe Kanagaratnam, Fabrice Hubelé, Elise Toussaint, Sylvain Choquet, Fontanet Bijou

EJNMMI Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K Bouabdallah, Fontanet Bijou

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Fontanet Bijou

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Thomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Fontanet Bijou

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, Charles Herbaux, Anne Banos, Fontanet Bijou

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study.
David Morland, Lukshe Kanagaratnam, Fabrice Hubelé, Elise Toussaint, Sylvain Choquet, Fontanet Bijou

Hemasphere· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
Julien Labreuche, Deborah Assouan, Eric Durot, Cecile Tomowiak, Damien Roos-Weil, Fontanet Bijou

Hematol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, Fontanet Bijou, Thomas E Witzig

EJHaem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Emmanuel Bachy, Roch Houot, Pierre Feugier, Krimo Bouabdallah, Reda Bouabdallah, Fontanet Bijou

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.
Elsa Maitre, Cécile Tomowiak, Benjamin Lebecque, Fontanet Bijou, Khaled Benabed

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Fontanet Bijou

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Gabriel Etienne, Carole Faberes, Fréderic Bauduer, Didier Adiko, François Lifermann, Fontanet Bijou

Cancer Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
Lucie Oberic, Frederic Peyrade, Mathieu Puyade, Christophe Bonnet, Peggy Dartigues-Cuillères, Fontanet Bijou

J Clin Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
Hervé Ghesquières, Cédric Rossi, Fanny Cherblanc, Sandra Le Guyader-Peyrou, Fontanet Bijou

BMC Public Health· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Gabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, Didier Adiko, François Lifermann, Fontanet Bijou

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis